Loading…
← CockpitCompetitor Analysis › 207940.KS Samsung BiologicsOpen in the cockpit ↗

Samsung Biologics207940.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology

World's largest biologics contract manufacturer, producing biotech drugs and antibody-drug conjugates for global pharma clients.

≈ Korea's Lonza/Catalent — a pure-play biologics contract manufacturer.Momentum strong 77
Mkt cap
$48.7B
US dollars, full cap
Free float
26%
of shares outstanding
$/day
$73.1M
20-day average traded
Fwd P/E
34.4×
forward earnings
ROIC−WACC
+13.3 pp
WACC 5.6%
Hurdle
-24 pp
Req g minus delivered
Next earnings
70 days
27 Jan 2027
Close · KRW₩1,366,000
1D-3.4%
1W-4.5%
1M-1.8%
3M-11.8%
6M-5.7%
YTD-19.4%
1Y-27.2%
ATR %4.7%
52w lowhigh31.2% off high

What Samsung Biologics does

World's largest biologics contract manufacturer, producing biotech drugs and antibody-drug conjugates for global pharma clients.

Customers sign multi-year contracts that reserve manufacturing capacity and pay per batch made, with development work up front as a way of locking in later production. Samsung C&T, the group's de facto holding company, is the largest shareholder. Growth has come from adding large plants in Songdo, South Korea, in stages, each filled by contracts agreed years ahead.

In one line: Korea's Lonza/Catalent — a pure-play biologics contract manufacturer..

Products and services

  • Biologics drug substance manufacturing
  • Fill-finish/drug product
  • Contract development (CDO)
  • Biosimilar development (via Samsung Bioepis)

Customers

  • global pharma/biotech companies (e.g., Pfizer, Mod

Where it sits in the supply chain

  • Pharma manufacturing
  • Contract development & manufacturing…
  • Mammalian-cell bioreactor drug…

What could go right

  • Biologics/ADC outsourcing growth
  • New plant capacity ramp

What could go wrong

  • Customer concentration in top clients
  • Biopharma capex cycle

Moat: wide (scale, regulatory licence, installed base). World's largest biologics manufacturing capacity; FDA/EMA-approved plants are costly to replicate or switch away from.

Headquarters: Incheon, South Korea · Founded: 2011 · Employees: 5,455

Named competitors

Samsung Biologics at a glance

Size Samsung Biologics (207940.KS) is a South Korea Health Care company (Biotechnology) with a market value of $48.7B, the 5th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩1,366,000 on 18 Nov 2026.

Performance Over six months the shares fell 5.7%, against +31.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 15 in its peer set.

Growth Revenue fell 20.5% over the last twelve months (peer median +13.9%); the operating margin is 43.4% (peer median 24.6%).

Valuation It trades at 34.4× forward earnings against a peer median of 25.2× (3rd most expensive of 11).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +31%, so the hurdle is -24 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.3 points above its cost of capital (5.6% WACC).

Next results Next results expected around 27 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 130207940.KS 96
Six months, rebased to 100: Samsung Biologics against the median of its 14 peers (local-currency closes).

Samsung Biologics financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩4.38T₩4.56T₩3.50T₩3.69T₩3.00T
Revenue growth—+30%-5%+23%—
Gross profit₩2.27T₩2.48T₩1.68T₩1.77T₩1.44T
EBITDA₩2.33T₩2.70T₩1.92T₩1.60T₩1.29T
Net income₩1.80T₩1.78T₩1.08T₩858B₩798B
Free cash flow₩1.45T₩856B₩356B₩671B-₩3.79B
Capital expenditure₩806B₩1.48T₩1.38T₩1.11T₩1.01T
Total debt₩1.04T₩927B₩1.49T₩1.91T₩2.51T

Quarterly statements and history in the cockpit →

Samsung Biologics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%-20%0%+20%LONNIQVNTRAARGXCSL068270GMABMRNA2269BNTXNBIXBBIOELAN207940.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Samsung Biologics is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%20×30×40×LONNIQVARGXCSL068270GMABUTHR2269NBIXELAN207940.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Samsung Biologics is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%LONNIQVARGXCSLUTHR2269ELAN207940.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Samsung Biologics is the large dot.

Samsung Biologics competitors and peer comparison

Head to head with its named competitors (207940.KS vs LONN.SW vs 2269.HK vs TMO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Samsung Biologics 207940.KS$48.7B-6%-20%43%34.4×7.0%
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Wuxi Bio 2269.HK$23.1B+35%+22%32%26.5×20.8%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Celltrion 068270.KS$34.9B+12%+40%32%33.9×10.6%

How Samsung Biologics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Samsung Biologics against its 14 peers (data as of 18 Nov 2026)
Measure207940.KSPeer medianRank in peer set
1-month return-1.8%+4.7%6th lowest of 15
6-month return-5.7%+31.7%2nd lowest of 15
Distance from 52-week high-31.2%-12.4%3rd lowest of 15
Revenue growth (TTM)-20.5%+13.9%2nd lowest of 15
Operating margin43.4%24.6%2nd highest of 15
Forward P/E34.4×25.2×3rd most expensive of 11
Growth the price implies (Req g, 7 yrs)7.0%11.6%4th least demanding of 11
Growth delivered (Del g)+31.4%+17.1%2nd highest of 11
Hurdle (Req g minus delivered)-24.3 pp-7.5 pp2nd least demanding of 11
ROIC minus cost of capital+13.3 pp+0.3 pp4th highest of 15
EV / EBITDA27.3×16.4×2nd most expensive of 11
Net debt / EBITDA-0.6×1.5×4th least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Samsung Biologics 207940.KSSouth Korea$48.7B-6%-20%43%34.4×7.0%+31.4%
Lonza LONN.SWSwitzerland$53.9B+36%-11%25%36.1×15.6%+7.7%
Iqvia IQVUnited States$42.5B+50%+9%14%18.7×16.8%+7.5%
Natera NTRAUnited States$42.0B+41%+37%-9%n/an/an/a
argenx SE Sponsored ADR ARGXUnited States$59.1B+17%+71%29%29.0×11.7%+151.4%
CSL CSL.AXAustralia$63.7B+102%-2%26%21.5×6.8%+11.0%
Celltrion 068270.KSSouth Korea$34.9B+12%+40%32%33.9×10.6%+17.6%
Genmab A/S GMAB.CODenmark$30.8B+103%+15%31%40.9×11.6%+19.5%
Moderna MRNAUnited States$79.6B+309%+13%-116%n/an/an/a
United Therapeutics UTHRUnited States$24.6B+2%+2%44%23.9×0.3%+16.5%
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%26.5×20.8%+30.2%
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%n/an/an/a
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%21.5×32.9%+7.6%

Questions

Who are Samsung Biologics's main competitors?
Named competitors: Lonza (LONN.SW), WuXi Biologics (2269.HK), Catalent (private or unlisted), Boehringer Ingelheim (CDMO) (private or unlisted), Fujifilm Diosynth (private or unlisted), Thermo Fisher Scientific (TMO). The cockpit's measured peer set (industry) also includes Lonza (LONN.SW), Iqvia (IQV), Natera (NTRA), argenx SE Sponsored ADR (ARGX), CSL (CSL.AX), Celltrion (068270.KS).
Is Samsung Biologics expensive compared with its peers?
On forward p/e it trades at 34.4× against a peer median of 25.2×, 3rd most expensive of 11 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +31%, so the hurdle is -24 pp: the price already allows for a slowdown.
How has Samsung Biologics stock performed?
Over six months to 18 Nov 2026 the shares returned -5.7% against +31.7% for the median peer; over one year -27.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.